Abstract 466P
Background
The daycare caters to numerous cancer patients. Patient satisfaction is a surrogate estimator of the quality of healthcare. Determination of the factors responsible for this will help to improve patient care delivery.
Methods
Women with breast or ovarian malignancies undergoing chemotherapy at the medical oncology daycare unit from 1st January 2023 to 1st April 2023 were invited to complete the PSS questionnaire anonymously. The PSS tool is an abbreviated 28 item questionnaire related to administrative services, medical team members and the treating consultant. The response options comprised a 5-point Likert scale. The raw scores were linearly transformed to a 0-100 scale and patients scoring more than 60 were considered as satisfied.
Results
A total of 117 patients participated in the study. There was a high level of overall satisfaction rate (93.2%). Availability of social support and health insurance were significant determinants of patient satisfaction (p=0.0043 and p=0.0006 respectively). The median waiting time was 3 hours with a satisfaction rate of 84%. The satisfaction rate for secretarial assistance, medical staff and the treating physician were 94%, 94% and 93.2% respectively. The patients’ likelihood of returning to our daycare for and recommending it to others were 97.4% and 96.6% respectively.
Conclusions
Ensuring availability of social support, provision of health insurance and effective patient-physician communication is likely to increase patient satisfaction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract